Pliant Therapeutics Investor Relations Material
Latest events
Study Update
Pliant Therapeutics
Q2 2025
7 Aug, 2025
Q1 2025
8 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pliant Therapeutics Inc
Access all reports
Pliant Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company developing DNA-based therapeutics that enable patients to reverse fibrosis and related diseases. The company's lead product candidate, PRTX-100, is a proprietary plasmid DNA therapeutic that has completed Phase 2 testing in nonalcoholic steatohepatitis (NASH). PTI owns the rights to exclusive plasmid-based therapies optimized for solid tumors including breast and pancreatic cancers. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Key slides for Pliant Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Pliant Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Pliant Therapeutics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
PLRX
Country
🇺🇸 United States